Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
Vidhatha Reddy, 1 Eric J Yang, 2 Bridget Myers, 1 Wilson Liao 1 1San Francisco Department of Dermatology, University of California, San Francisco, CA, USA; 2Virginia Mason Medical Center, Seattle, WA, USACorrespondence: Vidhatha ReddyUCSF Psoriasis and Skin Treatment Center, 515 Spruce Street, San...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9c6744d582d543c9b1218ff58759eaf8 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Vidhatha Reddy, 1 Eric J Yang, 2 Bridget Myers, 1 Wilson Liao 1 1San Francisco Department of Dermatology, University of California, San Francisco, CA, USA; 2Virginia Mason Medical Center, Seattle, WA, USACorrespondence: Vidhatha ReddyUCSF Psoriasis and Skin Treatment Center, 515 Spruce Street, San Francisco, CA 94118, USATel +1 661-340-3418Email Vidhatha.reddy@ucsf.eduAbstract: Risankizumab-rzaa (Skyrizi®; AbbVie) is a humanized IgG monoclonal antibody directed against interleukin-23p19 (IL-23p19) indicated for the treatment of moderate-to-severe psoriasis in adults who are candidates for systemic therapy or phototherapy. Four pivotal Phase III trials: UltIMMa-1, UltIMMa-2, IMMhance, and IMMvent have demonstrated efficacy and safety in patients with moderate-to-severe plaque psoriasis. This review highlights important findings from these and other clinical trials that have evaluated risankizumab. In addition, we discuss the mechanism of action, pharmacokinetics/pharmacodynamics, dosing recommendations, drug interactions, other potential indications, and ongoing clinical trials.Keywords: risankizumab, plaque psoriasis, IL-23 inhibitor, biologics, safety, efficacy |
|---|